The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Vaccine
; 38(39): 6184-6189, 2020 09 03.
Article
em En
| MEDLINE
| ID: mdl-32747214
ABSTRACT
Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of inactivated viral vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of the vaccine platform. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed inactivated viral vaccines.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Viral
/
Vacinas Virais
/
Aprovação de Drogas
/
Infecções por Coronavirus
/
Medição de Risco
/
Pandemias
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article